The regulatory update responds to a 2024 legal petition filed by Humane World for Animals and the Humane World Action Fund. For years, the organizations argued that despite the FDA's stated goal of treating animal tests as the exception, existing language created a de facto requirement that discouraged firms from adopting modern alternatives. By clarifying that animal data is not legally mandatory, the agency hopes to accelerate the integration of organ-on-a-chip technologies, computational models, and human cell-based systems into the drug development pipeline.

Sara Amundson, president of the Humane World Action Fund, described the change as a historic milestone, noting that the industry had been at a standstill awaiting explicit federal clearance to shift strategies. This policy adjustment aligns with broader government initiatives to modernize scientific research. On September 21, the National Institutes of Health announced $88 million in funding for non-animal research, alongside new investments in AI-driven laboratories and robotics. The FDA will accept public comments on the proposed rule until December 7, 2026.